ES2176307T3 - Uso de sustrato y/o donante de sintasa de oxido nitrico, o un inhibidor de oxido nitrico para la fabricacion de medicamentos destinados al tratamiento de trastornos de la contractilidad uterina. - Google Patents

Uso de sustrato y/o donante de sintasa de oxido nitrico, o un inhibidor de oxido nitrico para la fabricacion de medicamentos destinados al tratamiento de trastornos de la contractilidad uterina.

Info

Publication number
ES2176307T3
ES2176307T3 ES95900759T ES95900759T ES2176307T3 ES 2176307 T3 ES2176307 T3 ES 2176307T3 ES 95900759 T ES95900759 T ES 95900759T ES 95900759 T ES95900759 T ES 95900759T ES 2176307 T3 ES2176307 T3 ES 2176307T3
Authority
ES
Spain
Prior art keywords
nitric oxide
substrate
uterine contractility
donor
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900759T
Other languages
English (en)
Inventor
Robert E Garfield
Chandra Yallampalli
Kristof Chwalisz
Radoslaw Bukowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2176307T3 publication Critical patent/ES2176307T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

DISMINORREA, SANGRADO UTERINO DISFUNCIONAL, PARTO PREMATURO Y POSTPARTO EN MAMIFEROS HEMBRAS SE TRATAN INHIBIENDO LA CONTRACTILIDAD UTERINA MEDIANTE LA ADMINISTRACION DE UN SUSTRATO DE SINTASA DE OXIDO NITRICO, UN DONANTE DE OXIDO NITRICO O AMBOS, OPCIONALMENTE EN COMBINACION CON UNO O MAS INHIBIDORES DE PROSTAGLANDINA, UNA PROSTACICLINA MIMETICA, UNA PROGESTINA, UN ANTAGONISTA DE OXITOCINA O UN {BE}-AGONISTA EN UNA CANTIDAD EFECTIVA PARA MEJORAR LOS SINTOMAS DE LAS MISMAS; Y MENSTRUACIONES INADECUADAS TRATADAS E INDUCCION DE ABORTO O ESTIMULACION DEL PARTO EN UNA HEMBRA PREÑADA SE LOGRA MEDIANTE LA ESTIMULACION DE LA CONTRACTILIDAD UTERINA MEDIANTE LA ADMINISTRACION A LA MISMA DE UN INHIBIDOR DE OXIDO NITRICO, SOLO O EN UNA COMBINACION DE UN ANTAGONISTA DE PROGESTERONA, UNA OXITOCINA O UN ANTAGONISTA DE ANALOGO DE OXITOCINA O PROSTAGLANDINA.
ES95900759T 1993-11-16 1994-11-17 Uso de sustrato y/o donante de sintasa de oxido nitrico, o un inhibidor de oxido nitrico para la fabricacion de medicamentos destinados al tratamiento de trastornos de la contractilidad uterina. Expired - Lifetime ES2176307T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15249693A 1993-11-16 1993-11-16

Publications (1)

Publication Number Publication Date
ES2176307T3 true ES2176307T3 (es) 2002-12-01

Family

ID=22543178

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900759T Expired - Lifetime ES2176307T3 (es) 1993-11-16 1994-11-17 Uso de sustrato y/o donante de sintasa de oxido nitrico, o un inhibidor de oxido nitrico para la fabricacion de medicamentos destinados al tratamiento de trastornos de la contractilidad uterina.

Country Status (20)

Country Link
EP (1) EP0730448B1 (es)
JP (1) JP4015185B2 (es)
KR (2) KR100358320B1 (es)
CN (1) CN1108795C (es)
AT (1) ATE212833T1 (es)
AU (2) AU8144594A (es)
BR (1) BR9408067A (es)
CA (1) CA2176721A1 (es)
CZ (1) CZ291475B6 (es)
DE (1) DE69429823T2 (es)
DK (1) DK0730448T3 (es)
ES (1) ES2176307T3 (es)
FI (1) FI962109A7 (es)
HU (1) HUT74465A (es)
NO (1) NO961993L (es)
NZ (1) NZ276105A (es)
PL (1) PL178174B1 (es)
PT (1) PT730448E (es)
SK (1) SK63396A3 (es)
WO (1) WO1995013802A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
UA57703C2 (uk) * 1995-03-14 2003-07-15 Шерінг Актієнгезеллшафт Спосіб стимуляції та спосіб інгібування дозрівання шийки матки
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
ITMI20002117A1 (it) * 2000-09-29 2002-03-29 Ibsa Inst Biochimique Sa Uso di sodio nitroprussiato in ostetricia e ginecologia
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001392A1 (fr) * 1992-07-01 1994-01-20 Meiji Seika Kabushiki Kaisha (-)-ritodrine

Also Published As

Publication number Publication date
PT730448E (pt) 2002-07-31
BR9408067A (pt) 1996-12-24
DE69429823T2 (de) 2002-08-22
NO961993D0 (no) 1996-05-15
ATE212833T1 (de) 2002-02-15
NZ276105A (en) 2001-04-27
AU8086398A (en) 1998-10-22
KR960705560A (ko) 1996-11-08
CA2176721A1 (en) 1995-05-26
WO1995013802A1 (en) 1995-05-26
EP0730448B1 (en) 2002-02-06
FI962109L (fi) 1996-07-15
SK63396A3 (en) 1997-03-05
CZ291475B6 (cs) 2003-03-12
NO961993L (no) 1996-07-12
DK0730448T3 (da) 2002-04-22
AU8144594A (en) 1995-06-06
HU9601299D0 (en) 1996-07-29
PL178174B1 (pl) 2000-03-31
FI962109A0 (fi) 1996-05-17
CN1108795C (zh) 2003-05-21
KR100358320B1 (ko) 2003-01-24
JP4015185B2 (ja) 2007-11-28
HUT74465A (en) 1996-12-30
JPH09505068A (ja) 1997-05-20
DE69429823D1 (de) 2002-03-21
AU732532B2 (en) 2001-04-26
EP0730448A1 (en) 1996-09-11
CN1135178A (zh) 1996-11-06
FI962109A7 (fi) 1996-07-15
PL314465A1 (en) 1996-09-16
KR100358319B1 (ko) 2002-10-25
CZ139096A3 (en) 1996-10-16

Similar Documents

Publication Publication Date Title
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
EP1253929A4 (en) USE OF RELAXIN FOR THE TREATMENT OF DISEASES CONTAINED BY VASCARIAL CONSTRUCTION
DE69311361D1 (de) Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
DK209088D0 (da) Medicinpraeparater, deres fremstilling og anvendelse
DE60040299D1 (de) Stickstoffmonoxid-donoren zum induzieren von neurogenese
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
TR199802769T2 (xx) Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
ATE476663T1 (de) Spiegel der müllerschen inhibierenden substanz und ovarialreaktion
PT730448E (pt) Utilizacao de um substrato de sintetase e/ou dador de oxido nitrico ou um inibidor de oxido nitrico para o fabrico de medicamentos para o tratamento de desordens da contractilidade uterina
DK1621207T3 (da) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
ES8801173A1 (es) Procedimiento de producir agentes terapeuticos y profilacticos para ulceras pepticas
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
ATE283061T1 (de) Verwendung einer pollenextrakt-enthaltenden verbindung zur behandlung von ödemen
NO168177C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polysykliske forbindelser
SE7701441L (sv) Nytt piperazinyluracilsalt
ATE251459T1 (de) Verwendung von dienogest in hoher dosierung
RU93054179A (ru) Новые сульфонамиды
MX9307718A (es) Nuevas sulfonamidas, procedimiento para su preparacion y preparados farmaceuticos que las contienen.
UA23882A (uk) Спосіб лікування виразкової хвороби дванадцятипало ї кишки
BG60887B1 (en) Thienethiopyran sulphonamide derivatives and their application in ophthalmological preparations
ES85805U (es) Nueva bolsa para compra